FBXO22 promotes the pathogenesis and progression of hepatocellular carcinoma by mediating ubiquitination and degradation of p21 [15], promotes the progression of liver cancer by mediating polyubiquitination and degradation of KLF4 [16], promotes the growth of lung cancer cells by mediating polyubiquitination and inactivation of LKB1 [28], and promotes the progression of cervical cancer by targeting p57Kip2 [29]. Here, KLF4 is linked to liver cancer.